These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 33085938

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
    [Abstract] [Full Text] [Related]

  • 3. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
    Kato Y, Mizuno T, Yamada S, Nakamura T, Itai S, Yanaka M, Sano M, Kaneko MK.
    Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
    [Abstract] [Full Text] [Related]

  • 4. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [Abstract] [Full Text] [Related]

  • 5. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK.
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [Abstract] [Full Text] [Related]

  • 6. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
    Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK.
    Oncotarget; 2015 Nov 03; 6(34):36003-18. PubMed ID: 26416352
    [Abstract] [Full Text] [Related]

  • 7. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
    Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.
    Cancer Sci; 2012 Nov 03; 103(11):1913-9. PubMed ID: 22816430
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.
    Cancer Sci; 2016 Sep 03; 107(9):1198-205. PubMed ID: 27294401
    [Abstract] [Full Text] [Related]

  • 10. Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin.
    Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M, Handa S, Mizuno T, Maeda K, Fukui M, Harada H, Kaneko MK, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2018 Nov 03; 37(5):233-237. PubMed ID: 30362932
    [Abstract] [Full Text] [Related]

  • 11. Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin.
    Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2015 Oct 03; 34(5):310-7. PubMed ID: 26492618
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PMab-52: Specific and Sensitive Monoclonal Antibody Against Cat Podoplanin for Immunohistochemistry.
    Yamada S, Itai S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Harada H, Kagawa Y, Ichii O, Konnai S, Kaneko MK, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2017 Oct 03; 36(5):224-230. PubMed ID: 28737447
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
    Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y, Narimatsu H.
    Cancer Sci; 2008 Jan 03; 99(1):54-61. PubMed ID: 17944973
    [Abstract] [Full Text] [Related]

  • 16. Establishment of Novel Monoclonal Antibody PMab-32 Against Rabbit Podoplanin.
    Honma R, Fujii Y, Ogasawara S, Oki H, Liu X, Nakamura T, Kaneko MK, Takagi M, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2016 Feb 03; 35(1):41-7. PubMed ID: 26788987
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    Xu M, Wang X, Pan Y, Zhao X, Yan B, Ruan C, Xia L, Zhao Y.
    BMC Cancer; 2019 Jun 17; 19(1):599. PubMed ID: 31208371
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
    Kato Y, Ohishi T, Kawada M, Maekawa N, Konnai S, Itai S, Yamada S, Kaneko MK.
    Biochem Biophys Rep; 2019 Mar 17; 17():23-26. PubMed ID: 30519645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.